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Introduction
In the early the 1990s, several epidemiological studies suggested
the therapeutic potentials of aspirin and other nonsteroidal anti-in-
flammatory drugs (NSAIDs) against colorectal neoplasms.1-4 Aspirin
and NSAID are known to inhibit the production of prostaglandins
(PG) via the inactivation of prostaglandin endoperoxide H synthase,5
also often called cyclooxygenase (COX). In addition, the inhibitory
effect of the drugs has been shown to contribute to their anti-cancer
properties. They can suppress the proliferation6,7 and migration of can-
cer cells,8 and can also express the production of certain angiogenic
factors by tumor cells in vitro.9 Moreover, these studies so provided
evidence that linked the anti-cancer properties of drugs to the inhibi-
tion of the inducible form of COX, i.e. COX-2, and showed that the
anti-cancer properties were not associated with the constitutive from
of COX, i.e. (COX-1). In other words, the effects outlined above, in-
cluding those on malignancies, are now believed to be partially medi-
ated via the aberrantly expressed COX-2. Although these studies were
performed mainly in colon cancer both in vivo and in vitro, the in-
volvement of this enzyme in carcinogenesis or cancer progression
other than colon has been reported.10-13
In this context, at least certain steps of carcinogenesis or prolif-
eration of thyroid cancer may be enhanced by the overexpression
of COX-2. In the present study, we determined the expression of




Thyroid cancer, thyroid adenoma, and Graves' disease tissues
were obtained from our hospital during surgery from 1985 to 1997.
Normal thyroid tissue specimens were obtained from residual nor-
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Although the inducible form of cyclooxygenase (COX), COX-2, is highly expressed in various cancers and it is also involved in cancer pro-
gression, its role in thyroid cancer is not fully understood. We assessed in the situ cyclooxygenase expression in normal thyroids (n=6), Graves'
thyroids (n=6), thyroid adenomas (n=12), thyroid follicular (n=15) and papillary carcinomas (n=30). In comparison to the constitutive expression
of COX-1, COX-2 was highly expressed in thyroid cancers (90.0% of thyroid papillary carcinomas and 73.3% of thyroid follicular carcinomas)
and moderately in thyroid adenomas (25.5%), but barely expressed in normal and Graves' thyroid tissues. This quantitative assessment em-
ployed immunohistochemical methods. Thereafter we compared the effect of COX-2 inhibition on a human follicular thyroid carcinoma cell line
(WRO), and a human papillary carcinoma cell line (NPA), using selective COX-2 inhibitor(NS-398). The treatment with 50 M NS-398 sup-
pressed the growth of the COX-2 expressing cells, NPA cells (37.7%;p<0.01) and WRO cells (10.1%;p<0.05). Moreover, at concentrations
100 M, NS-398 induced cell death a mitochondrial dysfunction. In addition, 50 M of NS-398 inhibited the activation of extracellular signal-
regulated kinase in NPA cells after the stimulation with fetal bovine serum. Our results indicate that COX-2 is involved in the progression of thy-
roid cancer.
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mal tissues of resected thyroid cancers. A written informed consent
was obtained from each patient. Complete pathological reports
were available for all the tissue samples.
Materials
Anti-human COX-1 antibody (mouse monoclonal), anti-human
COX-2 antibody (goat polyclonal), and NS-398 (N-〔2-(cyclohexyloxy)-
4-nitrophenyl〕-methane sulfonamide), a selective inhibitor of COX-
2, were purchased from Cayman Co. (Ann Arbor, MI, U.S.A.).
Etdrac (1.8-diethyl-1,3,4,9-tetrahydopyrano[3,4-b] indole-1-acetic
acid) was kindly provided by Nippon Shinyaku Co. (Kyoto,
Japan). The IC50 values of Etdrac for COX-1 and COX-2 are 15
M and 1.4 M, respectively.14 The IC50 values of NS-398 are 220
M and 1.77 M, for COX-1 and COX-2, respectively.15 PD98059,
a selective MEK inhibitor, was purchased from Sigma Chemical
Co.(St. Louis, MO, U.S.A.). Anti-extracelluar signal-regulated kinase
(Anti-ERK) and anti-phosphorylated ERK antibody (rabbit polyclonal)
were purchased from Transduction Laboratories (Lexington, KY,
U.S.A.) and New England Biolabs, Inc. (Beverly, MA, U.S.A.),
respectively.
Cell cultures
NPA cells, a human thyroid papillary carcinoma cell line,16,17 and
WRO cells, a human thyroid follicular carcinoma cell line,16 were
kindly provided by Dr. G.Juillard (University of Carfornia-Los
Angeles Medical Center).The cells were maintained in a humidi-
fied, 5% CO2 incubator at 37℃ covered with RPMI medium (for
NPA cells) or Ham's F-12 medium (for WRO cells) supplemented
with 10% fetal bovine serum (Gibco BRL, Invitrogen Japan K.K.,
Tokyo, Japan) and antibiotics (5,000 U/ml penicillin, 5mg/ml
streptomycin). The primary cultured thyrocytes were obtained sur-
gically from the patients with Graves' disease and maintained as
previously described.18
Immunohistochemistry
The tissues from thyroid glands with various diseases were em
bedded in paraffin, cut into 4 m thick sections and mounted on posi-
tively charged The superfrost slides. Sections were deparaffinized,
and rehydrated with graded alcohol solutions, and the endogenous
peroxidase activity was quenched by the immersion in 3% H2O2 in
methanol. The nonspecific binding was blocked with 10% mouse
(COX-1) or goat (COX-2) serum and the sections were incubated
with primary antibody to COX-1 (1:100 dilution) or to COX-2 (1:100
dilution,) for 1 hour at room temperature. After washing with PBS,
the sections were incubated with a biotinylated secondary anti-
mouse (COX-1) or -rabbit (COX-2) antibody for 12 minutes at
room temperature. Color development was performed by using an
avidin-biotin peroxidase complex solution and 3,3'-diamino benzidine.
The counterstaining was briefly performed in methylgreen. The
control slides were treated with isotype-matched IgG. The intensity
of COX-2 immunostaining was graded on the following scale:－ =no
staining, +/－ =equivocal staining, +=moderate to intense staining,
and ++=highest intensity staging by T.A and T.U, independently.
Western Blotting
The cells were grown to approximately 80% confluence. They
were then washed with PBS, lysed in an ice cold protein lysis buffer
[20 mM sodium phosphate (pH 7.4), 1% Nonidet P-40, 0.5% sodium
deoxycholate, and 0.1% SDS at 10mg/ml] with freshly added 20 M
phenylmethylsulphonyl fluoride . The protein content of the lysate
was determined by using the Bio-Rad Protein Assay (Bio-Rad
Laboratories, Hercules, CA, U.S.A.). The total protein (30 g per
lane) was separated by electrophoresis on 10% SDS acrylamide gel,
and transferred onto a nitrocellulose membrane. COX-1 or COX-2 sig-
nal was detected with the specific antibodies that were used in
immunohistochemistry and was visualized by a chemiluminescence
method using ECL Western Blotting Detection Systems (Amersham
Pharmacia Biotech, Buckinghamshire, England).
Reverse Transcriptase Polymerase Chain Reaction
The total RNA was extracted from the cells by using RNeasy
Mini Kit (Qiagen, Tokyo) according to the instructions provided
by the manufacturer. The first-strand cDNA was synthesized by re-
verse transcription at 42℃ for 30 minutes in a 20 l reaction mix-
ture containing 500 ng of total RNA and AMV RT (Takara shuzo
Co., Shiga, Japan). For PCR reactions, 4 l of denatured cDNA was
amplified in a 50 l final volume with 0.5 U Taq DNA polymerase
(Gibco BRL, Invitrogen Japan K.K., Tokyo, Japan), 1 mM of both
primers, and Taq buffer containing 1.5 mM MgCl2 with 1.5 mM of
each dNTP. PCR was performed in a thermal cycler using a pro-
gram of 25 cycles at 94℃ for 30 seconds, 60℃ for 30 seconds, 72
℃ for 90 seconds, followed by a 10 min extension at 72℃ . The
amplified products were subjected to electrophoresis on 2% agarose
gel. The specific primers for the COX-2 PCR were as follows; 5'-
TTCAAATGAGATTGTGGGAAAATTGCT-3' (forward primer),
5'-AGATCATCTCTGCCTGCCTGAGTATCTT-3' (reverse primer).
The predicted size of the fragment was 301bp.
Induction of apoptosis in NPA cells
NPA cells (5× 105/well) were cultured in RPMI containing 10%
fetal bovine serum with or without NS-398 for 48 hours. After cul-
tivation, DNA fragmentation and disruption of the mitochondorial
function were assayed. DNA fragmentation was quantified by the
percentage of cells with hypodiploid DNA, as described previously.19
Disruption of mitochondrial function was estimated by using a de-
crease in the mitochondrial membrane potential, as previously de-
scribed.20 In brief, the cells were incubated with a saturating amount of
DiOC6 (3,3'-dihexyloxacarbocyamine iodide, Fluoreszenz Technologie,
Grottenhofstr, Austria) at 37℃ for 15 minutes, washed, and ana-
lyzed by a flow cytometer (Epics XL, Beckman Coulter, Inc.,
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Fullerton, CA, U.S.A.).
Phosphorylated ERK assay
NPA cells were maintained until 80% confluency in 60 mm cul-
ture dishes. They were then washed once with PBS and pretreated
for 12 hours in RPMI containing 0.5% bovine serum albumin with
or without NS-398. Thereafter, the cells were stimulated with fetal
bovine serum, at a final concentration of 10% (v/v), for 5 minutes
and lysed in lysis buffer [150 mM sodium chloride, 20 mM of Tris
(pH 7.5), 1% TritonX-100, 5 mM EDTA, 50 mM sodium fluoride,
10% glycerol, and freshly added 1 mM Na3VO4 and 20 mM/ml
phenylmethylsulphonyl fluoride] after washing twice with ice-cold
PBS. Finally, 20 g of protein was applied to Western blot analysis
and the phosphorylated ERK or the total ERK protein signal was
analyzed using primary antibodies (1:1000 each).
Results
COX-2 protein expression in vivo
We first examined the expression of in situ COX-1 and COX-2
proteins in the various thyroid tissues. As demonstrated in Figure
1, the immunostaining for COX-1 was detected in the cytoplasm of
thyroid follicular epithelial cells in all the tissue samples that were
examined. However, some thyroid tissues did not express COX-2.
As summarized in Table 1, the proportion of the tissue samples
immunohistochemically positive for COX-2 was 27 of 30 (90.0%)
for papillary carcinoma, and 11 of 15 (73.3%) for follicular carci-
noma, and 3 of 12 (25.0%) for thyroid follicular adenoma. Only a
weak COX-2 signal was identified in some of the Graves' disease,
and the signal was bare detectable in the follicular epithelial cells
of the normal thyroid. The intensity of the COX-2 signal was not
uniform in the thyroid cancer samples, but varied from weak to
strong. These findings suggested that COX-2 is essentially ex-
pressed in the thyroid neoplasm.
COX-2 expression in vitro
In this study the findings of a constitutive expression of COX-1
and an aberrant expression of COX-2 in thyroid cancers are similar
to those reported in colon cancer.21,22 Thereafter we next examined
the expression of these cyclooxygenases in the following cells; pri-
mary thyrocytes, a human thyroid follicular cancer cell line WRO,
and a human thyroid papillary cancer cell line NPA. Western blot-
ting analysis demonstrated the expression of COX-1 protein in
these three types, even though the intensity of the signals were not
consistent (Figure 2A). In contrast to COX-1, COX-2 was barely
expressed in primary thyrocytes, but abundant in NPA and WRO
cells (Figure 2A). COX-2 protein expression was almost similar in
NPA and WRO cells. These findings were confirmed by the results
of the COX-2 mRNA analysis (Figure 2B). These results con-
firmed that the COX-2 expression was limited to thyroid cancer
cells.
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Figure 1. The representative results of the immunohistochemical examina-
tion for COX-1(left) and COX-2(right) in human thyroid tissues. COX-1
was constitutively expressed in the follicular epithelial cytoplasm of normal
thyroid (A), Graves' thyroid (B), follicular adenoma (C), follicular carci-
noma (D), papillary carcinoma (E). In comparison to COX-1, COX-2 was
not detected in the non-neoplastic thyroid tissues [normal thyroid (F) and
Graves' thyroid(G)], but easily detected in the follicular epithelial cyto-
plasm of thyroid neoplasm [follicular adenoma (H), follicular carcinoma
(I), papillary carcinoma (J)]. Magnification, ×400.































Table 1. COX-2 Immunohistochemistry
Immunoreactivity for COX-2 was graded as － no staining; +/－ equivocal staining;
+ moderate to intense staining; ++ highest intensity staining.
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COX-2 inhibition and cancer proliferation
We assessed the possible involvement of COX-2 in the prolifera-
tion of the thyroid cancer cells. For this purpose, we used two
COX-2 inhibitors. The first inhibitor was Etdrac, which selectively
inhibits COX-2 at low concentrations, but at high concentrations,
it inhibits both COX-1 and COX-2.14 The second inhibitor was NS-
398, a selective inhibitor of COX-215 (see Materials and Methods).
Both agents showed anti-proliferative effects in a dose-dependent
manner on thyroid cancer cells (Figure 3). This effect was more
profound in NS-398 treated NPA cells (37.7% reduction of the cell
number at 50 M for 96 h treatment, p<0.01), which expressed
higher levels of COX-2, in comparison to the WRO cells (10.9%,
at similar conditions, p>0.05, data not shown). When examined
microscopically, low concentration of NS-398 (50 M) induced
morphological changes in NPA cells which consisted of cytoplasmic
elongation (Figure 4B), whereas higher concentrations (100 and
200 M) caused apoptosis of these cells (Figure 4C and D). However,
this effect was not seen in the primary thyrocytes (Figure 4E and
F). Therefore, the antiproliferative effect of the COX-2 inhibitors
was observed only in thyroid cancer cells. These results indicate
that COX-2 is involved in thyroid cancer proliferation in vitro.
COX-2 inhibitor and apoptosis in thyroid cancer cell
Previous studies have shown that COX-2 inhibitors promote
apoptotic cell death in colon cancer cells.6,7 In the next series of ex-
periments, we examined whether the cell death that was observed
at higher concentrations of NS-398 (Figure 4C and D) was due to
apoptosis of the cancer cells. We treated NPA cells with 100 M
NS-398 for 48 hours, collected all the floating and dish-attached
cells, and then examined the cells for DNA fragmentation and re-
duced mitochondrial membrane potential. As shown in Figure 5, at
the high concentration, NS-398 reduced mitochondrial membrane
12
Figure 2. The COX-2 expression in the primary cultured thyrocytes (lane P)
and the human thyroid cancer cell lines, WRO (lane W) and NPA (lane N).
(A) Western blotting was performed on the three types of thyroid cells.
Equal amounts of protein (30 g/lane) were loaded onto a 10% SDS
polyacrylamide gel, electrophoresed, and subsequently transferred to nitro-
cellulose membrane. Western blot was probed with antibody specific for
COX-1 (lower panel) or COX-2 (upper panel). In lane PD, NPA cells were
treated with PD 98059, a specific MEK inhibitor, for 12 hours.
(B) RT-PCR was performed on the using the three types of thyroid cells.
The cDNA was synthesized by reverse transcriptase using the total RNA as
a template and 4 l of the cDNA was amplified using specific human
COX-2 primers.
Figure 3. The COX-2 inhibitors suppressed the growth of thyroid cancer cells.
NPA cells were grown in the presence of the indicated concentrations of
Etdrac (A) or NS-398 (B) for 96 hours and the number of cells was counted
at the indicated time. Growth of NPA cells was suppressed by 14.4%
(p<0.05) by 100 M of etdrac and 37.7% (p<0.01) by 50 M of NS-398.
Value are the mean ± SEM (n=4). Similar results were obtained in three
separate experiments.
Figure 4. The microscopic findings of NPA cells and primary thyrocytes
after 36 or 72 hours treatment with NS-398, respectively. Relative to the
control (A), 50 M(B) NS-398 suppressed NPA cell growth. At higher con-
centrations, the number of NPA cell was lower and condensed nuclei and
shrunken cytoplasm were observed (C; 100 M). This effect was more
prominent at 200 M (D). In comparison to NPA cells, no significant mor-
phological changes were noted between the control primary thyrocytes (E)
and those treated for 72 hours with 200 M NS-398 (F). Magnification,
×200
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potential in 34.7% of NPA cells. However, the same treatment
failed to induce a marked change in DNA fragmentation (data not
shown).
NS-398 regulates ERK
Our above results showed that NS-398 induced death of the thy-
roid cancer cell lines when used at high concentrations. However,
even at the low concentration, NS-398 suppressed thyroid cancer
cell growth without any significant apoptosis. Mitogen-activated
protein kinase is known to be activated by various stimuli that are
associated with cell growth and differentiation.23 Recent studies
have also shown that NSAIDs disrupt the endothelial cell tube for-
mation through inhibition of ERK activation.24 However, whether
or not COX-2 inhibitors including NS-398, are capable of inhibit-
ing ERK activation in thyroid cancer cells, has not been examined.
Therefore, we examined whether or not NS-398 can inhibit ERK
activation in thyroid cancer cell lines. NPA cells were pretreated
without serum for 12 hours, and then stimulated again with serum
for 5 minutes in order to analyze the activation of ERK. As ex-
pected, the activated ERK was increased by the serum stimulation
and this response was reduced in the presence of NS-398(Figure
6). These results indicated that NS-398 influenced the thyroid can-
cer cell growth via inhibition of ERK activation.
Discussion
Several proteins are involved in the process of carcinogenesis,
and some of these proteins may serve as potential targets for novel
anti-cancer agents. Among these proteins, COX-2 is one of the most
promising candidates because it is expressed in many neoplasms,10-13,21,22
is involved in cancer cell growth and progression,6-9 and is weakly
or not expressed in normal tissues, with some exceptions.5 Williams
et al25 showed that when the stromal cells express COX-2, they
play an important role in cancer progression by becoming a source
of vascular endothelial growth factor. In addition, these results in-
dicate the importance of COX-2 in cancer progression, because
COX-2 that is found in stromal cells is essentially induced by me-
diators origination from cancer cells. In this study, we demonstrated
that COX-2 was aberrantly expressed in the thyroid neoplasm in vivo
and in vitro, was similar to those in other studies.26-28 In addition,
this study found that inhibition of this findings that are enzyme
reduced cancer cell growth via the impairment of mitochondrial
function and inhibition of ERK activation, as demonstrated in
vitro.
Several studies have previously demonstrated that the COX-2
inhibitors exert an anti-neoplastic effect through induction of
apoptosis.5,6 We also showed here that NS-398 induces significant
growth suppression of NPA cells. Interestingly, the same agent sig-
nificantly reduced the mitochondrial membrane potential without
changing the hypodiploid DNA fraction (Figure 5). These results
do not allow us to make a firm conclusion on whether the cell
death observed in our study was apoptosis-related. Since COX-2
inhibitors open mitochondrial pores via a reduction of PGE2 pro-
duction,29 we assume that NPA cells underwent cell death due to
mitochondrial dysfunction.
Mitogen activated-protein kinase cascade is a well-recognized
chain of phosphorylase enzymes and is activated when the cells are
stimulated with growth signals. Previous studies have shown that
ERK is a member of this cascade and in cultured endothelial cells,
NSAID including NS-398 are known to disrupt endothelial tube
formation and promote cell death by inhibiting ERK activation.24
Our results clearly showed that NS-398 regulated ERK activation
in NPA cells (Figure 4). In contrast to these results, Xu et al30 dem-
onstrated that COX-2 was induced through the activation of ERK
in rat vascular smooth muscle cells. They also showed that acti-
vated ERK enhanced not only the transcription of COX-2 mRNA
but also prolonged the half-life of COX-2 mRNA. Other reports 31,32
have indicated that COX-2 is under the regulation of ERK. These
findings are quite the opposite of the hierarchy between COX-2
and ERK if COX-2 regulates ERK. The present results also
13
Figure 6. NS-398 inhibited ERK activation.
NPA cells were cultured without serum for 12 hours with or without NS-
398 and were stimulated with serum for 5 minutes (lane NS and lane Ctl,
respectively). After the lysis, 20 g of protein was separated on 10% SDS-
polyacrylamide gel and transferred onto a nitrocellulose membrane. A western
blot was performed with antibodies specific for activated ERK or total ERK.
As a positive control (lane PD) NPA cells were pretreated with MEK inhibitor,
PD98059 (20 M for 60 min) and thereafter stimulated with serum for 5 min.
Figure 5. The mitochondrial dysfunction in NPA cells treated with NS-398.
NPA cells were treated with 100 M of NS-398 for 48 hours. After the
treatment, the cultivated cells were incubated with DiOC6 and the reduc-
tion of the mitochondrial membrane potential was determined by flow
cytometry. The numbers represent the percentage of cells with reduced
mitochondrial membrane potential.
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showed that ERK regulates COX-2 expression (Figure 2A). Thus,
it is possible that MAP kinase pathways and COX-2 may play an
important role in cell growth following mutual activation. Since
COX-2 null cell can be induced to undergo apoptosis by COX-2
inhibitor,33 it is possible that NSAID can regulate ERK without
COX-2 inactivation.
In summary, we demonstrated in the present study the aberrant
expression of COX-2 in thyroid cancer tissues both in vitro and in
vivo, and that inhibition of COX-2 reduced cell growth and in-
duced cell death of NPA cells. Our results also demonstrated that
ERK may be regulated by COX-2 and vice versa.
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